Medical Advocates
Adefovir Dipivoxil (Hepsera)
 
Journal Abstracts, Posters, and
Commentaries

General Reports
 HBV
HBV/HIV
 HIV





 
Adefovir Main Page Main New/Newsworthy  Home Page      
Last Update:  January 26, 2015
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
                
 
Adefovir dipivoxil compassionate use program in Spain: efficacy and resistance analysis
Buti M, Rodríguez Frías F, Calleja JL, et al
Med Clin (Barc). 2007 Oct 27;129(15):566-70
 Abstract
 
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant
hepatitis B: Final long-term results.
 Schiff E, Lai CL, Hadziyannis S, et al  
 Liver Transpl. 2007 Jan 11;13(3):349-360
 Abstract
 
Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir.
Nekvindova J, Masek V, Veinlichova A, et al 
Xenobiotica. 2006 Dec;36(12):1165-77.
 Abstract
 
Functional involvement of multidrug resistance associated protein 4 (MRP4/ABCC4)
in the renal elimination of the anti-viral drugs, adefovir and tenofovir.
Imaoka T, Kusuhara H, Adachi M, et al 
Mol Pharmacol. 2006 Nov 16;
 Abstract
 
Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil
in healthy Chinese subjects.
Sun DQ, Wang HS, Ni MY, Wang BJ, Guo RC.
Br J Clin Pharmacol. 2006 Jul 21;
 Abstract

Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration.
 Kearney BP, Ramanathan S, Cheng AK   
J Clin Pharmacol. 2005 Aug;45(8):935-40.
Abstract
HBV/HIV Indications
                
 
Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of
lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
Ingiliz P, Valantin MA, Thibault V, et al  
Antivir Ther. 2008;13(7):895-900.
 Abstract
 
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and
HIV infection: ACTG A5127.
 Peters MG, Andersen J, Lynch P, et al
Hepatology. 2006 Nov;44(5):1110-6
 Abstract
 
The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals
co-infected with hepatitis B and HIV.
 Hannon H, Isnard Bagnis C, et al.
Nephrol Dial Transplant. 2004 Feb; 19(2):
 Abstract

Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance
Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic
Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine.
 Delaugerre C, Marcelin AG, Thibault V, et al.
 Antimicrob Agents Chemother 2002 May;46(5):1586-8
Abstract
   
  Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-
resistant hepatitis B virus: an open-label pilot study.
Benhamou Y, Bochet M, Thibault V, et al.
 Lancet 2001 Sep 1;358(9283):718-723
 Abstract
HIV Indications
                
 
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B a
nd HIV-1.
 Benhamou Y, Thibault V, Vig P, et al  
 J Hepatol. 2006 Jan;44(1):62-7
 Abstract

Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
 Saah AJ, Haas DW, DiNubile MJ, et al.
 J Infect Dis 2003 Apr 1;187(7):1157-62
 Abstract

Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and
efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
Skowron G, Kuritzkes DR, Thompson MA, et al.
 Infect Dis 2002 Oct 1;186(7):1028-33
 Abstract

The safety and efficacy of adefovir dipivoxil in patients with advanced HIV  disease:
a randomized, placebo-controlled trial. 
Fisher EJ, Chaloner K, Cohn DL, et al.
AIDS 2001 Sep 7;15(13):1695-1700
 Abstract

Tenofovir, Adefovir, and Zidovudine Susceptibilities of Primary Human Immunodeficiency
Virus Type 1 Isolates with Non-B Subtypes or Nucleoside Resistance.
Palmer S, Margot N, Gilbert H, et al.
AIDS Res Hum Retroviruses 2001 Aug 10;17(12):1167-1173
 Abstract

 Adefovir and tenofovir susceptibilities of hiv-1 after 24 to 48 weeks of adefovir
dipivoxil therapy: genotypic and phenotypic analyses of study gs-96-408.
Miller MD, Margot NA, Lamy PD,  et al  
 Acquir Immune Defic Syndr 2001 Aug 15;27(5):450-458
 Abstract
FULL TEXT ARTICLE
 Single-Dose Pharmacokinetics and Safety of the Oral Antiviral Compound Adefovir
Dipivoxil in Children Infected with Human Immunodeficiency Virus Type 1
Hughes WT, Shenep JL, Rodman JH,
Antimicrob Agents Chemother 2000 Apr;44(4):1041-1046
Paper
 

  

Adefovir Main Page Main New/Newsworthy  Home Page      

Adefovir Dipivoxil Journal Citations